Loading clinical trials...
Loading clinical trials...
Prospective Non-randomized Stratified Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) in Adults With Ph+ Chronic Myeloid Leukemia With Stable Deep Molecular Response
Conditions
Interventions
Imatinib
Nilotinib
+2 more
Locations
1
Russia
National Research Center for Hematology
Moscow, Russia
Start Date
January 15, 2020
Primary Completion Date
January 15, 2025
Completion Date
January 15, 2025
Last Updated
October 8, 2020
NCT06994676
NCT06523556
NCT06236724
NCT04195633
NCT05334069
NCT05362773
Lead Sponsor
National Research Center for Hematology, Russia
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions